Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Always ask FDA to show ID

Executive Summary

FDA warns consumers Nov. 12 about "a fraudulent scheme to extort money from consumers by callers who falsely identify themselves as FDA Special Agents" or other agency officials. FDA said calls entice consumers to purchase discounted drugs by wiring funds to addresses in the Dominican Republic. A follow-up call attempts to blackmail the consumer, insisting that a fine of several thousand dollars be sent to the DR to avoid incarceration or other legal action. "The public should note that no FDA official will ever contact a consumer by phone demanding money or any other form of payment. FDA officials always present identification in person when conducting official business," said Michael Chappell, acting associate commissioner for regulatory affairs, in the press release

FDA warns consumers Nov. 12 about "a fraudulent scheme to extort money from consumers by callers who falsely identify themselves as FDA Special Agents" or other agency officials. FDA said calls entice consumers to purchase discounted drugs by wiring funds to addresses in the Dominican Republic. A follow-up call attempts to blackmail the consumer, insisting that a fine of several thousand dollars be sent to the DR to avoid incarceration or other legal action. "The public should note that no FDA official will ever contact a consumer by phone demanding money or any other form of payment. FDA officials always present identification in person when conducting official business," said Michael Chappell, acting associate commissioner for regulatory affairs, in the press release.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel